MarketPulse
A

$AVBP

2 articles found
2 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Na

ArriVent Advances Dual-Target Cancer Drug as FDA Clears IND for Novel ADC

ArriVent BioPharma wins FDA clearance for ARR-002, a first-in-class dual-target ADC targeting ovarian and endometrial cancers, with Phase 1 trials expected in H2 2026.
AVBPantibody-drug conjugateovarian cancer
GlobeNewswire Inc.GlobeNewswire Inc.··Na

ArriVent to Showcase EGFR Inhibitor and Dual-Target ADC at 2026 AACR Meeting

ArriVent BioPharma presents preclinical data on firmonertinib and ARR-002 ADC at 2026 AACR Annual Meeting, highlighting oncology pipeline progress.
AVBPPhase 3 trialNSCLC